Gm-Csf
Lung Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
68 Active assets in the Lung Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Anusha Kalbasi | Phase 2 | BBB |
Carboplatin Guangdong Association of Clinical Trials | Phase 3 | BBB |
ETOPOSIDE Guangdong Association of Clinical Trials | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Guangdong Association of Clinical Trials | Phase 3 | BB |
Nivolumab Emory University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Gm-Csf is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →